NCT00286247View on ClinicalTrials.gov

Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

Not specified

Conditions
Locally Advanced Breast Cancer (LABC)
Interventions
GENETIC

INGN 201

Trial Locations (1)

77030

M.D. Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Introgen Therapeutics

INDUSTRY